EP Wealth Advisors LLC lessened its position in Allergan plc (NYSE:AGN) by 3.7% during the fourth quarter, Holdings Channel reports. The fund owned 29,729 shares of the company’s stock after selling 1,139 shares during the period. EP Wealth Advisors LLC’s holdings in Allergan were worth $4,863,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AGN. Avestar Capital LLC bought a new position in Allergan in the fourth quarter valued at $113,000. Focused Wealth Management Inc increased its stake in Allergan by 4,444.4% in the fourth quarter. Focused Wealth Management Inc now owns 818 shares of the company’s stock valued at $134,000 after acquiring an additional 800 shares during the last quarter. BB&T Investment Services Inc. increased its stake in Allergan by 1,308.2% in the third quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock valued at $139,000 after acquiring an additional 641 shares during the last quarter. Acropolis Investment Management LLC bought a new position in Allergan in the fourth quarter valued at $153,000. Finally, Field & Main Bank bought a new position in Allergan in the fourth quarter valued at $155,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.
In related news, CEO Brent L. Saunders purchased 3,300 shares of the firm’s stock in a transaction that occurred on Thursday, March 8th. The stock was bought at an average cost of $152.53 per share, with a total value of $503,349.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Matthew M. Walsh purchased 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 8th. The stock was bought at an average cost of $153.96 per share, with a total value of $153,960.00. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 7,200 shares of company stock valued at $1,108,267. 0.36% of the stock is owned by insiders.
A number of research firms recently commented on AGN. Wells Fargo & Co set a $245.00 target price on Allergan and gave the company a “buy” rating in a research note on Friday, January 5th. Credit Suisse Group set a $214.00 price target on shares of Allergan and gave the company a “buy” rating in a research report on Tuesday, December 19th. They noted that the move was a valuation call. Royal Bank of Canada set a $218.00 price target on shares of Allergan and gave the company a “buy” rating in a research report on Thursday, January 4th. Citigroup cut their price target on shares of Allergan to $215.00 and set a “buy” rating for the company in a research report on Tuesday, January 9th. Finally, Vetr lowered shares of Allergan from a “strong-buy” rating to a “buy” rating and set a $187.73 price target for the company. in a research report on Wednesday, December 6th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company. Allergan presently has an average rating of “Buy” and a consensus price target of $224.02.
Allergan plc (NYSE:AGN) opened at $167.06 on Thursday. Allergan plc has a one year low of $142.81 and a one year high of $256.80. The stock has a market cap of $54,730.00, a PE ratio of -13.93, a P/E/G ratio of 1.15 and a beta of 1.29. The company has a quick ratio of 1.06, a current ratio of 1.16 and a debt-to-equity ratio of 0.38.
Allergan (NYSE:AGN) last released its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. The company had revenue of $4.33 billion during the quarter, compared to the consensus estimate of $4.28 billion. During the same period in the prior year, the firm earned $3.90 earnings per share. Allergan’s revenue was up 12.0% on a year-over-year basis. analysts anticipate that Allergan plc will post 15.58 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be paid a $0.72 dividend. This is an increase from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 dividend on an annualized basis and a yield of 1.72%. The ex-dividend date of this dividend is Tuesday, February 27th. Allergan’s dividend payout ratio is presently -24.02%.
TRADEMARK VIOLATION WARNING: “Allergan plc (AGN) Shares Sold by EP Wealth Advisors LLC” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/15/allergan-plc-agn-shares-sold-by-ep-wealth-advisors-llc.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.